Posted by Michael Wonder on 18 Apr 2023
US FDA approves Qulipta (atogepant) for adults with chronic migraine
17 April 2023 - Qulipta now the first and only oral CGRP receptor antagonist approved to prevent migraine across frequencies, including episodic and chronic.
AbbVie today announced that the US FDA has approved expanding the indication of Qulipta (atogepant) for the preventive treatment of migraine in adults.
